Drug Trial Radar · NCT04561063
COVID-19 Prophylaxis South Africa (COVER HCW)
Last checked: Nov 19, 2026Latest source record: Jun 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,950
Actual
Start
Dec 8, 2020
Primary completion
Feb 28, 2022
Study completion Feb 28, 2022
Sponsor
- Lead sponsor
- University of Witwatersrand, South AfricaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomised, multi-center, open label, adaptive, exploratory trial to assess the efficacy of two different drug regimens in terms of preventing symptomatic COVID-19 disease in healthcare workers at high risk of exposure to SARS-CoV-2. The trial will compare two different experimental medication arms to the control arm comprising the use of standard personal protective equipment (PPE) with no additional pharmacological intervention.
Conditions
- Covid19
- SARS-CoV Infection
Interventions
NitazoxanideDrug
Nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (Participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)
Sofosbuvir/DaclatasvirDrug
Sofosbuvir/daclatasvir 400mg/60 mg sofosbuvir/daclatasvir fixed dose combination 1 tablet daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of SARS-CoV-2 infectionsTime frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, Gauteng, South Africa
Sunnyside Office Park
Johannesburg, Gauteng, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.